Aligos Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Aligos Therapeutics, Inc. (ALGS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.01% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-05
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.01%, a 110.00% decline from fiscal 2024.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.10%.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -0.63%.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was -1.91%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.01% 10-K · filed 2026-03-05 | |
| 2024-12-31 | 0.10% 10-K · filed 2026-03-05 | |
| 2023-12-31 | -0.63% 10-K · filed 2025-03-10 | |
| 2022-12-31 | -1.91% 10-K · filed 2024-03-12 | |
| 2021-12-31 | -0.31% 10-K · filed 2023-03-09 | |
| 2020-12-31 | 0.27% 10-K · filed 2022-03-10 | -0.17% 10-K · filed 2021-03-23 |
| 2019-12-31 | -1.32% 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |